secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001213900-23-010323
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma reports Q1 net loss of $3.6M ($0.02/sh); cash runway through Feb 2024
--------------------------------------------------------------------------------

- Net loss of $3.6M ($0.02 EPS) improved from $9.2M ($0.06 EPS) in Q1 2022.
- Cash and equivalents $36.9M; runway expected to fund operations through Feb 2024.
- I/ONTAK BLA under FDA review with PDUFA target date July 28, 2023.
- Mino-Lok Phase 3 trial expanding; enrollment uptick in U.S. and India.
- Director Dennis McGrath elected, replacing Dr. William Kane.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/0001213900-23-010323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/ea173123-8k_citiuspharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-010323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer